Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 57.57% is 243% above its 5-year average of -40.40%, around the middle of its 5-year range (-193.13%–270.57%).
17.82% above its 12-month average of 48.86%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 21.43%.
NET PROFIT MARGIN
57.57%
NET PROFIT MARGIN AVG TTM
48.86%
NET PROFIT MARGIN AVG 3Y
-29.11%
NET PROFIT MARGIN AVG 5Y
-40.40%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+17.82%
CURRENT VS 3Y AVG
+297.80%
CURRENT VS 5Y AVG
+242.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 711 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
LENSAR Inc
Market Cap
$82.53M
Net Profit Margin
57.57%
TTM Avg
48.86%
3Y Avg
-29.11%
5Y Avg
-40.40%
Market Cap
$82.73M
Net Profit Margin
-1168.20%
TTM Avg
-1464.39%
3Y Avg
-946.48%
5Y Avg
-672.82%
Market Cap
$83.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$83.48M
Net Profit Margin
-648.32%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$81.45M
Net Profit Margin
-430.43%
TTM Avg
-446.97%
3Y Avg
-347.08%
5Y Avg
-386.84%
Market Cap
$84.57M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-72272.26%
Market Cap
$84.78M
Net Profit Margin
-7884.06%
TTM Avg
-7191.86%
3Y Avg
-8225.67%
5Y Avg
-7676.39%
Market Cap
$85.01M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$80.04M
Net Profit Margin
-55.03%
TTM Avg
-63.48%
3Y Avg
-81.34%
5Y Avg
-87.39%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $82.53M | 57.57% | 48.86% | -29.11% | -40.40% |
| MediciNova, Inc. (MNOV)vs › | $82.73M | -1168.20% | -1464.39% | -946.48% | -672.82% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | -648.32% | 0.00% | 0.00% | 0.00% |
| Nutriband Inc. (NTRB)vs › | $81.45M | -430.43% | -446.97% | -347.08% | -386.84% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.57M | 0.00% | 0.00% | 0.00% | -72272.26% |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | -7884.06% | -7191.86% | -8225.67% | -7676.39% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pulmonx Corporation (LUNG)vs › | $80.04M | -55.03% | -63.48% | -81.34% | -87.39% |
| Humacyte, Inc. (HUMA)vs › | $85.13M | -4560.82% | -1001.79% | -692.03% | -1554.36% |
Operating Margin
-42.1%
Net Profit Margin
57.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 21.43% |
| 2026-03-31 | 270.57% |
| 2025-12-31 | -9.10% |
| 2025-09-30 | -25.94% |
| 2025-06-30 | -12.66% |
| 2025-03-31 | -193.13% |
| 2024-12-31 | -111.78% |
| 2024-09-30 | -11.09% |
| 2024-06-30 | -71.57% |
| 2024-03-31 | -20.37% |
| 2023-12-31 | -32.43% |
| 2023-09-30 | 26.22% |
| 2023-06-30 | -72.87% |
| 2023-03-31 | -51.77% |
| 2022-12-31 | -24.34% |
| 2022-09-30 | -51.51% |
| 2022-06-30 | -84.09% |
| 2022-03-31 | -71.46% |
| 2021-12-31 | -34.77% |
| 2021-09-30 | -74.41% |
| 2021-06-30 | -55.06% |
| 2021-03-31 | -73.58% |
| 2020-12-31 | -82.42% |
| 2020-09-30 | -66.66% |
| 2020-06-30 | -89.10% |
| 2020-03-31 | -62.41% |
| 2019-12-31 | -29.17% |
| 2019-09-30 | -72.11% |
| 2019-06-30 | -45.51% |
| 2019-03-31 | -45.51% |
